Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Deffered Revenue (2021 - 2025)
Historic Non-Current Deffered Revenue for Viridian Therapeutics, Inc.\DE (VRDN) over the last 5 years, with Q2 2025 value amounting to $140000.0.
- Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue fell 6728.97% to $140000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was $140000.0, marking a year-over-year decrease of 6728.97%. This contributed to the annual value of $284000.0 for FY2024, which is 5043.63% down from last year.
- Per Viridian Therapeutics, Inc.\DE's latest filing, its Non-Current Deffered Revenue stood at $140000.0 for Q2 2025, which was down 6728.97% from $212000.0 recorded in Q1 2025.
- In the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue ranged from a high of $1.1 million in Q4 2021 and a low of $140000.0 during Q2 2025
- Its 5-year average for Non-Current Deffered Revenue is $644600.0, with a median of $645000.0 in 2023.
- Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue crashed by 2506.53% in 2022 and then plummeted by 6728.97% in 2025.
- Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Non-Current Deffered Revenue stood at $1.1 million in 2021, then dropped by 25.07% to $861000.0 in 2022, then crashed by 33.45% to $573000.0 in 2023, then crashed by 50.44% to $284000.0 in 2024, then tumbled by 50.7% to $140000.0 in 2025.
- Its Non-Current Deffered Revenue stands at $140000.0 for Q2 2025, versus $212000.0 for Q1 2025 and $284000.0 for Q4 2024.